Type 1 and type 2 diabetic patients display different patterns of cellular microparticles

被引:341
作者
Sabatier, F
Darmon, P
Hugel, B
Combes, V
Sanmarco, M
Velut, JG
Arnoux, D
Charpiot, P
Freyssinet, JM
Oliver, C
Sampol, J
Dignat-George, F
机构
[1] Univ Mediterranee, INSERM, UFR Pharm, Lab Immunol & Hematol, Marseille, France
[2] Federat Autoimmun & Thrombosis, AP HM Concept, Marseille, France
[3] AP HM Nord, Dept Endocrinol Metab Dis & Nutr, Marseille, France
[4] Inst Hematol & Immunol, Fac Med, Strasbourg, France
[5] AP HM Nord, Dept Internal Med, Marseille, France
关键词
D O I
10.2337/diabetes.51.9.2840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of vasculopathies in diabetes involves multifactorial processes including pathological activation of vascular cells. Release of microparticles by activated cells has been reported in diseases associated with thrombotic risk, but few data are available in diabetes. The aim of the present work was to explore the number and the procoagulant activity of cell-derived microparticles in type I and 2 diabetic patients. Compared with age-matched control subjects, type I diabetic patients presented significantly higher numbers of platelet and endothelial microparticles (PAH and EMP), total annexin V-positive blood cell microparticles (TMP), and increased levels of TMP-associated procoagulant activity. In type 2 diabetic patients, only TMP levels were significantly higher without concomitant increase of their procoagulant activity. Interestingly, in type 1 diabetic patients, TMP procoagulant activity was correlated with HbA(1c,) suggesting that procoagulant activity is associated with glucose imbalance. These results showed that a wide vesiculation process, resulting from activation or apoptosis of several cell types, occurs in diabetes. However, diabetic patients differ by the procoagulant activity and the cellular origin of microparticles. In type I diabetic patients, TIAP-procoagulant activity could be involved in vascular complications. Moreover, its correlation with HbA(1c), reinforces the importance of an optimal glycemic control in type 1 diabetes.
引用
收藏
页码:2840 / 2845
页数:6
相关论文
共 40 条
[1]   Molecular basis for a link between complement and the vascular complications of diabetes [J].
Acosta, J ;
Hettinga, J ;
Flückiger, R ;
Krumrei, N ;
Goldfine, A ;
Angarita, L ;
Halperin, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5450-5455
[2]   The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection [J].
Aupeix, K ;
Hugel, B ;
Martin, T ;
Bischoff, P ;
Lill, H ;
Pasquali, JL ;
Freyssinet, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1546-1554
[3]   Activated polymorphonuclear leukocytes and monocytes in the peripheral blood of patients with ischemic heart and brain conditions correspond to the presence of multiple risk factors for atherothrombosis [J].
Berliner, S ;
Rogowski, O ;
Rotstein, R ;
Fusman, R ;
Shapira, I ;
Bornstein, NM ;
Prochorov, V ;
Roth, A ;
Keren, G ;
Eldor, A ;
Zeltser, D .
CARDIOLOGY, 2000, 94 (01) :19-25
[4]   Diabetes and endothelial dysfunction: A clinical perspective [J].
Calles-Escandon, J ;
Cipolla, M .
ENDOCRINE REVIEWS, 2001, 22 (01) :36-52
[5]   Neutrophil-endothelial cells modulation in diabetic patients undergoing coronary artery bypass grafting [J].
Chello, M ;
Mastroroberto, P ;
Cirillo, F ;
Bevacqua, E ;
Carrano, A ;
Perticone, F ;
Marchese, AR .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1998, 14 (04) :373-379
[6]   In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant [J].
Combes, V ;
Simon, AC ;
Grau, GE ;
Arnoux, D ;
Camoin, L ;
Sabatier, F ;
Mutin, M ;
Sanmarco, M ;
Sampol, J ;
Dignat-George, F .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :93-102
[7]  
Combes V, 1997, THROMB HAEMOSTASIS, V77, P220
[8]   Platelet vesiculation in angina patients treated with coronary angioplasty [J].
Combes, V ;
Joly, P ;
Ambrosi, P ;
Sabatier, F ;
Camoin, L ;
Pili, J ;
Sampol, J ;
Dignat-George, F .
THROMBOSIS AND HAEMOSTASIS, 2000, 83 (03) :518-518
[9]  
Cosentino F, 1998, J CARDIOVASC PHARM, V32, pS54
[10]  
Galli M, 1996, THROMB HAEMOSTASIS, V75, P427